RedHill Biopharma (RDHL) Accumulated Expenses (2016 - 2025)

RedHill Biopharma (RDHL) has 10 years of Accumulated Expenses data on file, last reported at $12.0 million in Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $12.0 million, up 20.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $12.0 million (up 20.24% YoY), and the FY2025 annual result was $12.0 million, up 20.24% from the prior year.
• Accumulated Expenses climbed to $12.0 million in Q4 2025 per RDHL's latest filing, from $10.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $25.4 million in Q1 2021 and troughed at $4.0 million in Q2 2024.
• A 5-year average of $16.0 million and a median of $17.9 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses slumped 74.42% in 2023, then jumped 169.78% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $20.9 million in 2021, then dropped by 14.1% to $17.9 million in 2022, then tumbled by 74.42% to $4.6 million in 2023, then soared by 117.62% to $10.0 million in 2024, then rose by 20.24% to $12.0 million in 2025.
• Business Quant data shows RDHL's Accumulated Expenses at $12.0 million in Q4 2025, $10.7 million in Q2 2025, and $10.0 million in Q4 2024.